BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lippi G, Mattiuzzi C, Henry BM. Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variant. J Med Virol 2022. [PMID: 34988998 DOI: 10.1002/jmv.27575] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lepelletier D, Chidiac C, Mansour Z, Chauvin F; High Council for Public Health working group. New French guidelines to adapt the "Isolate/Detect/Trace" strategy for COVID-19 adult peoples or contacts considering the exponential spread of Omicron variant. Health Sci Rep 2022;5:e612. [PMID: 36254238 DOI: 10.1002/hsr2.612] [Reference Citation Analysis]
3 Xu A, Hong B, Lou F, Wang S, Li W, Shafqat A, An X, Zhao Y, Song L, Tong Y, Fan H. Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention. MedComm 2022;3. [DOI: 10.1002/mco2.172] [Reference Citation Analysis]
4 Mattiuzzi C, Henry BM, Lippi G. Regional Association between Mean Air Temperature and Case Numbers of Multiple SARS-CoV-2 Lineages throughout the Pandemic. Viruses 2022;14:1913. [DOI: 10.3390/v14091913] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Brehm J, Spaeth A, Dreßler L, Masetto T, Dannenberg R, Peter C, Grimmler M. SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study. Front Immunol 2022;13:915338. [DOI: 10.3389/fimmu.2022.915338] [Reference Citation Analysis]
6 Patel RS, Agrawal B. Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. Front Immunol 2022;13:952229. [DOI: 10.3389/fimmu.2022.952229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Merza MA, Almufty HB. The Omicron Variant is Striking Iraqi Kurdistan in January 2022: Would Preventive Measures Contain the new Wave? Disaster Med Public Health Prep 2022;:1-2. [PMID: 35676252 DOI: 10.1017/dmp.2022.156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lapa D, Grousova DM, Matusali G, Meschi S, Colavita F, Bettini A, Gramigna G, Francalancia M, Garbuglia AR, Girardi E, Puro V, Antinori A, Kovyrshina AV, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Gushchin VA, Logunov DY, Naroditsky BS, Vaia F, Gintsburg AL. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. Vaccines 2022;10:817. [DOI: 10.3390/vaccines10050817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
9 Lippi G, Favresse J, Gromiha MM, SoRelle JA, Plebani M, Henry BM. Ad interim recommendations for diagnosing SARS-CoV-2 infection by the IFCC SARS-CoV-2 variants working group. Clin Chem Lab Med 2022. [PMID: 35452576 DOI: 10.1515/cclm-2022-0345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Lippi G, Henry BM, Plebani M. LumiraDX SARS-CoV-2 Antigen Test for Diagnosing Acute SARS-CoV-2 Infection: Critical Literature Review and Meta-Analysis. Diagnostics (Basel) 2022;12:947. [PMID: 35453996 DOI: 10.3390/diagnostics12040947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Lippi G, Henry BM, Adeli K, Plebani M. Fujirebio Lumipulse SARS-CoV-2 antigen immunoassay: pooled analysis of diagnostic accuracy. Diagnosis (Berl) 2022. [PMID: 35287253 DOI: 10.1515/dx-2022-0021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bhattacharya M, Sharma AR, Dhama K, Agoramoorthy G, Chakraborty C. Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions. Geroscience 2022. [PMID: 35258772 DOI: 10.1007/s11357-022-00532-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
13 Антонец Д, Старчевская М, Колосова Н, Суслопаров И, Даниленко А, Боднев С, Швалов А, Трегубчак Т, Рыжиков А, Пьянков О, Максютов Р. Предварительный анализ генетической изменчивости изолятов вируса SARS-CoV-2, относящихся к варианту Омикрон, циркулирующих на территории Российской Федерации.. [DOI: 10.21055/preprints-3112049] [Reference Citation Analysis]
14 Rizzo A, Palmiotti G. SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate. Future Oncol 2022. [PMID: 35109688 DOI: 10.2217/fon-2022-0024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]